Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857653 | 0.80 | TRPV4 (0.33) | L3MBTL1POLBALDH1A1MAPTMAPK1 | |
| SCHEMBL8198902 | 0.79 | L3MBTL1 (0.51) | L3MBTL1POLBALDH1A1MAPTMAPK1 | |
| SCHEMBL2415067 | 0.79 | L3MBTL1 (0.51) | L3MBTL1POLBALDH1A1MAPTMAPK1 | |
| SCHEMBL8193031 | 0.74 | L3MBTL1 (0.50) | L3MBTL1POLBALDH1A1MAPTMAPK1 | |
| SCHEMBL6190450 | 0.70 | HRH4 (0.42) | L3MBTL1POLBALDH1A1MAPTKDM4E | |
| SCHEMBL6050316 | 0.67 | SMN1; SMN2 (0.36) | ALDH1A1MAPTMAPK1KDM4EKMT2A | |
| SCHEMBL24894462 | 0.66 | TRPV4 (0.36) | ARTRPV4 | |
| SCHEMBL18805561 | 0.66 | TRPV4 (0.45) | L3MBTL1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL14963036 | 0.66 | KDM4E (0.51) | L3MBTL1ALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL8646982 | 0.64 | KDM4E (0.34) | L3MBTL1POLBALDH1A1KDM4ECYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11049676-A | — | — | None | — | — | JP | disclosed |
| JP-11049777-A | — | — | None | — | — | JP | disclosed |
| JP-11049678-A | — | — | None | — | — | JP | disclosed |
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-109071560-B | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | 瓦洛健康公司 | 2022-01-14 | — | — | CN | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| CN-109071560-A | Thienopyridine formamide as ubiquitin-specific protease inhibitor | 福马治疗股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-3414252-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139778-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| EP-1109796-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | Geron Corporation (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001002377-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
| JP-H1149777-A | HETERO FIVE-MEMBERED RING-CONDENSED PYRIDINE-BASED TELOMERASE INHIBITOR | GERON CORP | 1999-02-23 | — | — | JP | disclosed |
| JP-H1149676-A | PYRIDINE-BASED TELOMERASE INHIBITOR | GERON CORP | 1999-02-23 | — | — | JP | disclosed |
| JP-H1149678-A | PYRIDINE-BASED TELOMERASE INHIBITOR | GERON CORP | 1999-02-23 | — | — | JP | disclosed |
| US-5770613-A | PYRIDINE DERIVATIVES; ANTICARCINOGENIC AGENTS | GERON CORPORATION (US) | 1998-06-23 | — | — | US | disclosed |
| US-5767278-A | ANTICARCINOGENIC AGENTS | GERON CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| US-5760062-A | ANTICANCER AGENTS | GERON CORPORATION (US) | 1998-06-02 | — | — | US | disclosed |
| US-5703116-A | TREATING CANCER | GERON CORPORATION (US) | 1997-12-30 | — | — | US | disclosed |
| US-5656638-A | ANTICANCER, ANTITUMOR AGENTS | GERON CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | L3MBTL1 1107/4885POLB 2905/4885ALDH1A1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.